Jazz Pharmaceuticals Files 2024 Annual Report Amendment

Ticker: JAZZ · Form: 10-K/A · Filed: Apr 25, 2025 · CIK: 1232524

Jazz Pharmaceuticals PLC 10-K/A Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type10-K/A
Filed DateApr 25, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: amendment, annual-report, pharmaceuticals

TL;DR

Jazz Pharma filed its 2024 10-K amendment. All good.

AI Summary

Jazz Pharmaceuticals plc filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 25, 2025, provides updated information for the company, which is incorporated in Ireland and operates in the pharmaceutical preparations industry. The company's principal executive offices are located in Dublin.

Why It Matters

This amendment provides updated financial and operational information for Jazz Pharmaceuticals, crucial for investors and stakeholders to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This filing is an amendment to an annual report, typically containing updated disclosures rather than significant new risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 10-K/A filing?

This filing is an Amendment No. 1 to the Annual Report (Form 10-K) for the fiscal year ended December 31, 2024, indicating updates or corrections to the original filing.

When was this amendment filed with the SEC?

This amendment was filed on April 25, 2025.

What is Jazz Pharmaceuticals plc's primary industry?

Jazz Pharmaceuticals plc is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.

Where is Jazz Pharmaceuticals plc incorporated?

Jazz Pharmaceuticals plc is incorporated in Ireland.

What is the SEC file number for Jazz Pharmaceuticals?

The SEC file number for Jazz Pharmaceuticals is 001-33500.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 25, 2025 regarding Jazz Pharmaceuticals plc (JAZZ).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing